ADVENT On Air

ADVENT Program
  • 4.7 (14)
  • MEDICINE
  • UPDATED MONTHLY

The latest updates in type 2 inflammatory science, brought to you by leading experts in the field. The ADVENT On Air podcast will feature scientific conversations that explore new research into the pathologies and modalities for a range of diseases linked to type 2 inflammation (atopic dermatitis, asthma, prurigo nodularis, chronic rhinosinusitis with nasal polyps, and eosinophilic esophagitis). This podcast is instrumental for healthcare professionals focused on allergy, dermatology, gastroenterology, and diseases of the upper and lower airways who want to stay at the forefront of this complex, evolving disease area. Subscribe to the ADVENT On Air podcast channel to receive notifications when new episodes are released. To explore additional educational materials for HCPs about dermatology, pulmonology, rhinology, and gastroenterology, visit ADVENTprogram.com. This podcast is produced as part of ADVENT, a medical education non-promotional program organized by Sanofi and Regeneron, and is intended for healthcare professionals. ©2023 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved. MAT-GLB-2302644 v2.0 07/2023 MAT-US-2304947 v1.0-P Exp. Date 07/07/2025

  1. JAN 30

    Breath, Blood, and Beyond: The Prognostic Power of Biomarkers in Asthma Across Ages

    Join pediatric respirologist Dr. Sharon Dell and adult respirologist Dr. Simon Couillard as they discuss the prognostic and diagnostic power of asthma biomarkers and their impact on optimizing patient management across all ages. ADVENT is a medical education non-promotional program for healthcare professionals organized by Sanofi and Regeneron.   This podcast is intended for healthcare professionals only. Disclaimer: This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits Speaker disclosures:   Dr. Simon Couillard: he has received non-restricted research grants from the NIHR Oxford BRC, the Quebec Respiratory Health Research Network, the Association Pulmonaire du Québec, the Academy of Medical Sciences, AstraZeneca, bioMérieux, Circassia Niox Group, and Sanofi-Genyme-Regeneron; he is the holder of the Association Pulmonaire du Québec’s Research Chair in Respiratory medicine and is a Clinical research scholar of the Fonds de recherche du Québec; he received speaker honoraria from AstraZeneca, GlaxoSmithKline, Sanofi-Regeneron, Circassia Niox Group and Valeo Pharma; he received consultancy fees for FirstThought, Apogee Therapeutics, Upstream Bio, AstraZeneca, GlaxoSmithKline, Sanofi-Regeneron, Access Biotechnology and Access Industries; he has received sponsorship to attend/speak at international scientific meetings by/for AstraZeneca and Sanofi-Regeneron. He is an advisory board member and detains stock options for Biometry Inc – a company which is developing a FeNO device (myBiometry); he is co-inventor for the patent filed as ‘Method for alleviating dyspnea with neuromodulation’. He advised the Institut national d'excellence en santé et services sociaux (INESSS) for an update of the asthma general practice information booklet for general practitioners as well as therapeutic indications for Enerzair, and is a member of the asthma steering committee of the Canadian Thoracic Society, 2025-05-26 Dr. Sharon Dell: Grants and Research Support: Boehringer Ingelheim, Merck, Parion Sciences, Sanofi, VertexPharmaceuticals; Honoraria or Consultation Fees: AstraZeneca, Novartis, Regeneron Pharmaceuticals Inc., Sanofi   © 2026 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved. MAT-GLB-2506512 - 1.0 - 01/2026 MAT-US-2600428 v1.0 - P Expiration Date: 01/16/2028

    31 min

  2. JAN 30

    Disease Modification in Severe Asthma: Framework, Assessment, and Clinical Impact

    Join Profs. Brusselle and Backer as they discuss the concept of disease modification in asthma. Join them as they highlight  the concept of disease modification in severe asthma, how it can be defined and objectively assessed, and the benefits for the patient when disease modification is a treatment target.   ADVENT is a medical education non-promotional program for healthcare professionals organized by Sanofi and Regeneron.   This podcast is intended for healthcare professionals only. Disclaimer: This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits Speaker disclosures:   Dr. Vibeke Backer: has worked as an advisor, supervisor, and investigator of pharmaceutical studies and has received unrestricted grants from AstraZeneca, GSK, MSD & Schering Plough, ALK-Abelló, Nycomed, Chiesi, Novartis, Pharmaxis, Nigaard, Pfizer, Boehringer Ingelheim, Maribo Medico, Aerocrine, Teva, Sanofi, Regeneron, and BIRK NPC. Dr. Guy Bruselle:  has received grants from Merck Sharp & Dohme and has recevied lecturer/consultant fees from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Merck Sharp & Dohme, Novartis, and Sanofi   © 2026 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved. MAT-GLB-2503097 - 1.0 - 01/2026 MAT-US-2600873 v1.0 - P Expiration Date: 01/28/2028

    21 min

  3. JAN 28

    Be on the Lookout for EoE: The Importance of Early Diagnosis

    Hear Dr. Seema Aceves and Ms. Hilary Ugras discuss the importance of early diagnosis and intervention for patients with EoE, opportunities for early diagnosis, and unmasking the adaptive behaviors of patients with EoE.  ADVENT is a medical education non-promotional program for healthcare professionals organized by Sanofi and Regeneron.  Learn more at ADVENTprogram.com.  This podcast is intended for healthcare professionals only.  Disclaimer:   This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc.  The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program  The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits    Speaker disclosures:   Dr. Seema Aceves: Research funding: NIH, NIAID, NIDDK . Honoraria and/or consultation fees: AstraZeneca, Medscape, UpToDate, Regeneron, Sanofi, Ferring . Other support: Royalties, Co-inventor, oral viscous budesonide (UCSD-patented, Takeda-licensed)  Ms. Hilary Ugras: Consultant/Speaker/Advisory Board: Regeneron, Sanofi, Takeda  © 2026 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved.  MAT-GLB-2506205 - 1.0  - 01/2026  MAT-US-2512929 v1.0 - P Exp Date: 01/23/2028

    18 min

  4. JAN 26

    Predictors of Recurrence in CRSwNP

    Hear Drs. Katie Buchheit and Martin Wagenmann discuss the rates of recurrence following endoscopic sinus surgery for patients with CRSwNP and different methods of predicting which patients will respond well to surgery and which patients would fare better with a different approach. ADVENT is a medical education non-promotional program for healthcare professionals organized by Sanofi and Regeneron. This podcast is intended for healthcare professionals only. Disclaimer: This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits Speaker disclosures:   Dr. Katie Buchheit: K. Buchheit has served on scientific advisory boards and/or received honoraria from AstraZeneca, Regeneron, Sanofi-Genzyme, Eli Lilly and GlaxoSmithKline, receives royalties from UpToDate, and receives research funding from NIH/NIAID and Regeneron. Dr. Martin Wagenmann: Fees for lectures and / or participation in scientific advisory boards: Advanz Pharma, ALK-Abelló, Allergopharma, AstraZeneca, Celltrion, CSL Behring, GSK, HAL Allergie, med update, MSD, NeilMed, Regeneron, Sanofi, Stallergenes, Streamed Up; Grants (to institution): ALK-Abelló, AstraZeneca, EU, GSK, Novartis, Regeneron, Sanofi, Takeda © 2026 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved. MAT-GLB-2506006 - 1.0  - 1/2026 MAT-US-2600233 v1.0 - P Exp Date: 01/07/2028

    21 min

  5. JAN 9

    Best Practice for CSU - Perspectives from Allergy and Dermatology

    Join allergist Dr. Nicole Chase and dermatologist Dr. Jason Hawkes as they dispel common myths in the management of chronic spontaneous urticaria. offering practical, empathetic strategies to move beyond unnecessary diagnostics and delays, focusing instead on urgent treatment escalation and effective management to reduce the profound burden of uncontrolled CSU on patients. ADVENT is a medical education non-promotional resource for healthcare professionals organized by Sanofi and Regeneron. Learn more at ADVENTprogram.com. This podcast is intended for healthcare professionals only. Disclaimer: This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program. The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits. Speaker disclosures: Nicole Chase, MD, has the following interests to disclose: ALK, Amgen, Apogee, ARS, AstraZeneca, Aquestive, Blueprint, Cogent, Eli Lilly, Genentech, Illuminate Health, Incyte, MJH Life Sciences, Novartis, Onviv, Regeneron, Sanofi, Regeneron, Vindico. Jason Hawkes, MD, MS has the following interests to disclose: Medical Board, National Psoriasis Foundation Scientific Advisory Committee, Apogee, Arcutis Biotherapeutics, Boehringer Ingelheim, Blueprint Medicines, Bristol Myers Squibb, Boxer Capital LLC, Cogent Biosciences, Galderma, Institute for Systems Biology, Janssen, LEO Pharma, Novartis, Regeneron, Sanofi, SUN Pharma, Takeda, UCB. © 2026 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved. MAT-GLB- MAT-GLB-2506315 – 1.0 – 01/2026 MAT-US-2514202 v1.0 - P Expiration Date: 12/24/2027

    29 min

  6. 12/09/2025

    Eosinophilic Esophagitis: Steering Toward Success

    Hear Drs Evan Dellon and Joshua Wechsler discuss EoE assessment utilizing the latest guidance from both US and European guidelines. Join them as they discuss current approaches to assess treatment response, the need for maintenance therapy, and the importance of follow-up and looking beyond symptom improvement to define therapeutic success.   ADVENT is a medical education non-promotional program for healthcare professionals organized by Sanofi and Regeneron.   This podcast is intended for healthcare professionals only. Disclaimer: This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits Speaker disclosures:   Dr. Evan Dellon: Research funding:  Adare/Ellodi, Allakos, Arena/Pfizer, AstraZeneca, Celldex, Dr. Falk Pharma, Eupraxia, Ferring, GSK, Meritage, Miraca, Nutricia, Celgene/Receptos/BMS, Regeneron, Revolo, Sanofi, Shire/Takeda, Uniquity; Consultant:  Abbvie, Adare/Ellodi, Alfasigma, ALK, Allakos, Amgen, Apogee, Apollo, Aqilion, Arena/Pfizer, AstraZeneca, Biocryst, Bryn, Calypso, Celgene/Receptos/BMS, Celldex, Domain, EsoCap, Eupraxia, Dr. Falk Pharma, Ferring, GI Reviewers, GSK, Holoclara, Invea, Knightpoint, LucidDx, Nexstone Immunology/Uniquity, Nutricia, Parexel/Calyx, Phathom, Regeneron, Revolo, Robarts/Alimentiv, Roivant, Sanofi, Shire/Takeda, Target RWE, Third Harmonic Bio, Upstream Bio; Educational grant:  Allakos, Aqilion, Holoclara, Invea  Dr. Joshua Wechsler: Medical advisory/speaker/consultant: Regeneron/Sanofi; Consultant: AstraZeneca, Ellodi, Celldex; Medical Advisory: BMS  © 2025 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved. MAT-GLB-2503560 - 2.0 - 12/2025

    17 min

  7. 08/27/2025

    Burden of Disease and Diagnosis

    Drs Donna Culton and Russell Hall explore the Burden of Disease and Diagnosis of BP. ADVENT is a medical education non-promotional resource for healthcare professionals organized by Sanofi and Regeneron. Learn more at ADVENTprogram.com.   This podcast is intended for healthcare professionals only.   Disclaimer: This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program. The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits. Speaker disclosures: Dr. Culton - Consultant/advisory board or principal investigator: Argenx, Cabaletta, iCell, Incyte, Janssen, Lilly, Regeneron, Sanofi Genzyme, Sitala  Dr. Hall - Consultant and/or grant: Argenx, Sanofi/Regeneron, GycoEra, NUVIG, Immunovant, Innovaderm, Priovan Therapeutics    © 2025 Sanofi and Regeneron Pharmaceuticals, Inc. AllRights Reserved. MAT-GLB-2501573 – 1.0 – 06/2025

    19 min

  8. 02/27/2025

    Exploring the Urgency to Treat Patients with Atopic Dermatitis

    Join Prof. Lisa Beck as she explores the chronic and persistent burden of AD as well as the concept of early intervention.   ADVENT is a medical education non-promotional resource for healthcare professionals organized by Sanofi and Regeneron. Learn more at ADVENTprogram.com.   This podcast is intended for healthcare professionals only.   Disclaimer: This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program. The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits.   Speaker disclosures: Lisa Beck MD, consults for Abbvie, Allakos, Arcutis Biotherapeutics, Arena Pharmaceuticals, Aslan Pharma, Astria Therapeutics, Celldex, Dermavent, DermTech, Escient Pharma, Eli Lilly Company, Evelo Biosciences, Galderma, Incyte, Janssen, LEO Pharma, Merck, Nektar Therapeutics, Numab Therapeutics, Pfizer, Proteologix, Rapt Therapeutics, Regeneron, Ribon Therapeutics, Sanofi/Genzyme, Sanofi-Aventis, Sitryx Therapeutics, Stealth BioTherapeutics, Trevi Therapeutics, Union Therapeutics, Xencor and Yuhan and has been an Investigator for Abbvie, Astra-Zeneca, DermTech, Kiniksa, Pfizer, Regeneron, Ribon Therapeutics and Sanofi.    © 2025 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved. MAT-GLB-2407353  – 1.0 – 02/2025 MAT-US-2501683 v1.0 - P Expiration Date: 02/24/2027

    15 min
See All (24)

Ratings & Reviews

4.7
out of 5
14 Ratings

About

The latest updates in type 2 inflammatory science, brought to you by leading experts in the field. The ADVENT On Air podcast will feature scientific conversations that explore new research into the pathologies and modalities for a range of diseases linked to type 2 inflammation (atopic dermatitis, asthma, prurigo nodularis, chronic rhinosinusitis with nasal polyps, and eosinophilic esophagitis). This podcast is instrumental for healthcare professionals focused on allergy, dermatology, gastroenterology, and diseases of the upper and lower airways who want to stay at the forefront of this complex, evolving disease area. Subscribe to the ADVENT On Air podcast channel to receive notifications when new episodes are released. To explore additional educational materials for HCPs about dermatology, pulmonology, rhinology, and gastroenterology, visit ADVENTprogram.com. This podcast is produced as part of ADVENT, a medical education non-promotional program organized by Sanofi and Regeneron, and is intended for healthcare professionals. ©2023 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved. MAT-GLB-2302644 v2.0 07/2023 MAT-US-2304947 v1.0-P Exp. Date 07/07/2025

Information

  • Creator
    ADVENT Program
  • Years Active
    2023 - 2026
  • Episodes
    24
  • Rating
    Clean
  • Show Website
    ADVENT On Air